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H-Y minor histocompatibility antigens and the development of
chronic graft versus host disease (cGVHD) after allogeneic
hematopoietic stem cell transplantation (HSCT). These ﬁnd-
ings suggest that donor B cells play a role in the development of
cGVHD and clinical trials utilizing anti-CD20 monoclonal an-
tibody, rituximab, have demonstrated clinical improvement in
some patients with active resistant cGVHD. B cell activating
factor, BAFF, is a member of the TNF cytokine family that
binds to one of three cell surface receptors on B cells. Activation
of these B cell receptors by antigen and BAFF results in rapid
induction of proliferation and differentiation of germinal center
B cells into either Ig-secreting cells or memory B cells. The
ﬁnding that elevated BAFF levels in patients with autoimmune
diseases are associated with disease severity and autoantibody
production has led to clinical trials using anti-BAFF monoclonal
antibody in these diseases. To test whether BAFF contributes to
the activation of B cells in patients with cGVHD, we employed
a sandwich ELISA to measure soluble BAFF in plasma from 27
patients after allogeneic HSCT. Mean BAFF levels for extensive
(n  8), limited (n  8), resolved (n  6) or no (n  5) cGVHD
groups were: 7.3 ng/ml, 5.37 ng/ml, 3.92 ng/ml and 2.02 ng/ml,
respectively. The differences between the extensive or limited
groups versus the no cGVHD group were statistically signiﬁcant
(each P  .03) suggesting that BAFF levels corresponded with
cGVHD activity. B cell subsets in peripheral blood were also
examined by ﬂow cytometry to identify circulating memory B
cells. Of four cGVHD patients analyzed thus far, individuals
with active disease and high BAFF levels also had high numbers
of CD27 memory B cells in peripheral blood compared to
patients with resolved cGVHD and low BAFF levels. Ongoing
prospective, serial assessment of BAFF levels and B cell pheno-
type in larger numbers of patients will extend these results. We
propose that BAFF may serve as a new biomarker for cGVHD,
speciﬁcally identifying patients with active disease. If further
studies identify a pathologic role for increased BAFF in
cGVHD, anti-BAFF monoclonal antibodies may provide a new
therapeutic approach for this serious complication of allogeneic
HSCT.
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TREATMENT OF MURINE ACUTE GVHD WITH THE NOVEL PRO-APOP-
TOTIC BENZODIAZEPINE BZ-423
Gatza, E.1, Clouthier, S.1, Rogers, C.1, Liu, C.2, Reddy, P.1,
Glick, G.D.1, Ferrara, J.L.M.1 1. University of Michigan Comprehen-
sive Cancer Center, Ann Arbor, MI; 2. University of Florida College of
Medicine, Gainesville, FL.
Bz-423 is a novel 1,4-benzodiazepine with both cytotoxic and
cytostatic effects on activated lymphocytes. Bz-423 has been
shown to suppress lupus in murine models by eliminating patho-
genic lymphocytes without altering normal immune function or
overt toxicities. We hypothesized that Bz-423 might enhance
the apoptotic deletion of alloreactive donor T cells and there-
fore reduce graft-versus-host disease (GVHD). We ﬁrst inves-
tigated the effect of Bz-423 on activated T cells in vitro. A 40
M concentration of Bz-423 induced apoptotic death in 	90%
of both CD4 and CD8 T lymphocytes stimulated with allo-
geneic dendritic cells (DC) or ConA in the presence of synge-
neic DC. Puriﬁed resting T cells were signiﬁcantly less suscep-
tible to Bz-423-induced apoptosis (data not shown). We next
examined the effect of Bz-423 in vivo utilizing a well-charac-
terized (Balb/c3B6) murine GVHD model. B6 recipient mice
were conditioned with 11 Gy total body irradiation and injected
with 5.0  106 bone marrow and 4-5.0  106 puriﬁed T cells
from either syngeneic (B6) or allogeneic (Balb/c) donors. In
order to model the administration of Bz-423 as a treatment
strategy rather than a prevention strategy, animals were not
treated for the ﬁrst seven days after BMT. Beginning 7 days
following BMT and continuing for the remainder of the exper-
iment, Bz-423 was administered i.p. at a dose of 60 mg/kg three
times weekly. As shown in the table below, treatment with
Bz-423 resulted in signiﬁcantly better day 60 survival (P 
.001) and reduced clinical GVHD scores (P  .02) among
allogeneic BMT recipients. Bz-423 also reduced GVH-associ-
ated immunodeﬁciency (P  .02) and decreased liver and gut
histopathology of GVHD (P  .01). Delay of the onset of
treatment to day 14 post-BMT also resulted in a signiﬁcant
survival beneﬁt (P  .03). These data demonstrate that Bz-423
can reverse acute GVHD and induce selective apoptosis of
alloreactive donor T cells in this model. Pro-apoptotic benzo-
diazepines may provide a strategy for the treatment of acute
GVHD (Table 1).
Table 1.
Syn 
Bz
Allo 
vehicle
Allo 
Bz
P
Value1
Treatment onset:
day 7
Survival (day 60) 100% (n  9) 8% (n  13) 59% (n  19) .001
GVHD clinical
score
(day 60)2
1.5  0.2 6.5  0.0 3.1  0.4 <.02
Pathology
(day 74)3
Liver 1.3  0.6 13.7  1.5 8.3  2.5 .01
Intestine 3.0  2.0 21.3  6.0 10.0  0.8 .01
Splenic
reconstitution
(day 74)3
T cells (106) 20.6  1.8 1.4  0.02 3.6  0.4 .02
B cells (106) 41.6  12.6 2.5  0.7 21.2  15.6 .02
Treatment onset:
day 14
Survival (day 60) 100% (n  3) 20% (n  5) 71% (n  6) .03
1Calculated at the 95% conﬁdence level, Allo  vehicle vs Allo 
Bz-423; 2reported as mean clinical score  SE; 3reported as mean
value  SD.
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OPPOSING EFFECTS OF ICOS ON GRAFT-VERSUS-HOST DISEASE MEDI-
ATED BY CD4 AND CD8 T CELLS
Yu, X.-Z.1, Liang, Y.1, Roza, N.I.2, Anasetti, C.1, Dong, C.2 1. H. Lee
Mofﬁtt Cancer Center, Tampa, FL; 2. M.D. Anderson Cancer Center,
Houston, TX.
Inducible costimulatory molecule (ICOS), a CD28 family mem-
ber expressed on activated CD4 and CD8 T cells, plays im-
portant roles in T cell activation and effector function. Here we
studied the role of ICOS in graft-versus-host disease (GVHD)
mediated by CD4 or CD8 T cells in allogeneic bone marrow
transplantation (BMT). In comparison of wild type (WT) and
ICOS-deﬁcient T cells, we found that recipients of ICOS/
CD4 T cells exhibited signiﬁcantly less GVHD morbidity and
mortality. ICOS/ CD4 T cells had no defect in expansion,
but expressed signiﬁcantly less FasL and produced signiﬁcantly
lower levels of IFN- and TNF-
. Thus, ICOS/ CD4 T
cells were impaired in effector functions that lead to GVHD. In
contrast, recipients of ICOS/ CD8 T cells exhibited signif-
icantly enhanced GVHD morbidity and mortality. In the absence
of ICOS signaling, either using ICOS-deﬁcient donors or ICOS-
ligand deﬁcient recipients, the levels of expansion and Tc1 cyto-
kine production of CD8 T cells were signiﬁcantly increased. The
level of expansion was inversely correlated with the level of
apoptosis, suggesting that increased ability of ICOS/ CD8 T
cells to induce GVHD was resulted from the enhanced survival and
expansion of those cells. Our ﬁndings indicate that ICOS has
paradoxical effects on the regulation of alloreactive CD4 and
CD8 T cells in GVHD.
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HIGHER CLEARANCE RATES OF MYCOPHENOLATE MOFETIL (MMF) IN
PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (AlloSCT) RECIPI-
ENTS
Militano, O.1, Roache, K.2, Shaw, L.M.3, Figurski, M.3, Satwani, P.2,
Ayello, J.2, Roman, E.2, Del Toro, G.2, Bradley, B.2, George, D.2,
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Garvin, J.H.2, Bhatia, M.2, Wolownik, K.2, Foley, S.2, Hawks, R.2,
Cairo, M.S.2,4,5 1. Department of Pharmacy, New York Presbyterian
Hospital, New York, NY; 2. Department of Pediatrics, Columbia Uni-
versity, New York, NY; 3. Pathology and Laboratory Medicine, Univer-
sity of Pennsylvania, Philadelphia, PA; 4. Department of Pathology,
Columbia University, New York, NY; 5. Department of Laboratory
Medicine, Columbia University, New York, NY.
To date there are no published data on pharmacokinetics (PK) of
MMF in children undergoing AlloSCT. The objective of this study
is to evaluate effects of age on the PK of MMF in pediatric
AlloSCT pts. From 1/04-9/05 we enrolled 26 pediatric AlloSCT
with 23 being evaluable: mean age 7.6 yrs; wt 31.6 kg; M:F 
11:12; NBL PR (n  3), SCD (n  2), AML (CR1 [n  3], CR2
[n 1], CR3 [n 1], relapsed/induction failure [n 2]), SAA (n
4), CML CP (n  1), ALL (CR1 [n  1], CR2 [n  2], CR3 [n 
1]), HD CR2 (n  1), ALCL refractory (n  1); donor sources:
MFD (6/6 PBSC [n  6], 6/6 BM [n  2], 5/6 PBSC [n  2]), 6/6
related CB (n  1), UCB (6/6 [n  2], 5/6 [n  2], 4/6 [n  7]),
and 8/10 MUD PBSC (n  1). Cohort 1 (6 yrs) (n  8); 2 (6-12
yrs of age) (n  8); 3 (12-16 yrs) (n  7). GVHD prophylaxis
included tacrolimus (starting on day 1 or 1st day of conditioning
to maintain concentrations 5-20 ng/mL) and MMF (900 mg/m2/
dose IV Q6h starting on day1, then converted to PO [same dose]
after day 14). Serum samples for MPA assay were drawn on day
1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6 post-dose. MPA
plasma concentrations were determined by reverse-phase HPLC.
MMF dose was adjusted to maintain MPA trough 1-3.5 mg/L. The
mean CD34 cell dose/kg  25.8  105, TNC dose/kg  48 
107. Time to neutrophil (ANC 500/mm3  2 d) and platelet
engraftment (untransfused count20K  7 d) were 22 d and 39 d.
The mean f/u was 278 d. Mean MPA PK on day 14: Cmax 
12.4 mg/L, total MPA trough  0.9 mg/L, AUC0-12  32.7 mg 
hr/L, Css  2.7 mg/L, T1/2  1.5 h , Vss  1.8 L/kg, and CL 
1.4 L/kg/h at a mean MMF dose of 1080 mg/m2 IV Q6h. The
breakdown of age cohorts is shown in Table 1. Incidence of GI
adverse events attributable to MMF was 65% (nausea/vomiting
[n  12], diarrhea [n  7], abdominal pain [n  3], pneumatosis
intestinalis [n  1], colitis [n  1]). Incidence of grade II-IV
aGVHD was 59% (13/22 evaluable pts) and cGVHD was 26.3%
(5/19 evaluable pts). Kaplan-Meier probability of 1 year OS was
70.4% (CI: 49.7-91.1%). In comparison to MMF PK in adult
AlloSCT pts receiving cyclosporine/MMF (Nash et al, Biol Blood
Marrow Transplant, 2005), children have signiﬁcantly higher MMF
clearance rates (1.4 vs 0.54 L/kg/h). MMF doses 	3-fold higher
than those used in pediatric SOT recipients were required to
achieve AUC0-12  30-60 mg  h/L. Short half-life (1.5 hrs) and
rapid clearance of MMF in pediatric AlloSCT pts may be related to
a lack of enterohepatic recycling and enhanced UDP-glucurono-
syltransferase activity (Table 1).
Table 1. Mean Age-Related IV MMF PK on Day 14
Age
Group
Cmax
(mg/L)
Total
MPA
Trough
(mg/L)
Free
MPA
Trough
(ng/mL)
AUC 0–12
(mg  hr/L)
Total
Css
(mg/L)
T1/2
(hr)
CL
(L/kg/hr)
<6 y.o. (n  6) 12.2 1.0 18.7 34.0 2.8 1.8 1.6
6–12 y.o. (n  5) 11.8 0.4 14.8 29.5 2.5 1.1 1.4
12–16 y.o. (n  2) 14.4 1.4 17.9 39.9 3.3 1.5 0.6
Cmax  peak concentration; MPA  mycophenolic acid; AUC 
area under the curve; Css steady state concentration; T1/2
half-life; CL  clearance.
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THE ROLE OF MHC CLASS II IN CD4CD25 T CELL-MEDIATED FACIL-
ITATION OF ALLOGENEIC HEMATOPOIETIC ENGRAFTMENT AND SUP-
PRESSION OF GVHD
Hanash, A.M., Jones, A., Levy, R.B. University of Miami Miller School
of Medicine, Miami, FL.
In recent years there has been signiﬁcant interest in the potential
of CD4CD25 regulatory T cells to suppress GVHD and pro-
mote allogeneic engraftment. In a MHC-mismatched model uti-
lizing C57BL/6 (B6) T cell-depleted bone marrow and sublethally
conditioned (7.0 Gy TBI) BALB/c recipients, we have demon-
strated that co-transplanted donor CD4CD25 T cells are capa-
ble of supporting multi-potential and lineage-committed donor
progenitor activity as well as long-term chimerism and tolerance.
Little is currently understood regarding the antigen recognition
initiating regulatory cell function during hematopoietic transplan-
tation, and we have employed our in vivo model toward elucidating
the antigenic requirements involved in the initial promotion of
allogeneic engraftment. Transplanting BALB/c  B6 F1
CD4CD25 T cells (1  106) with B6 marrow (2  106) signif-
icantly increased B6 CFU-GM in BALB/c recipients seven days
post-BMT (P  .001 vs. BM alone), demonstrating that donor
CD4CD25 T cells did not require alloreactivity to support
hematopoietic progenitors. Furthermore, B6 CD4CD25 T cells
failed to augment MHC-disparate C3H/HeJ CFU-GM in BALB/c
recipients (P 	 .05 vs. BM alone), suggesting that donor
CD4CD25 T cells might require recognition of syngeneic
MHC for progenitor support. Indeed, augmentation of donor
CFU-GM was abrogated when B6 CD4CD25 T cells were
co-transplanted with B6-MHC class II/ marrow into BALB/c
recipients (P 	 .05 vs. BM alone). CD4CD25 T cell-mediated
augmentation of donor chimerism two months post-BMT was also
abrogated by co-transplantation with MHC II/ marrow. In
order to compare the role of MHC class II in progenitor support
vs. suppression of GVHD, a model of CD8-mediated GVHD was
utilized: co-transplanted BALB/c CD4CD25 T cells were able
to prevent the GVHD mediated by highly puriﬁed BALB/c CD8
T cells in B6-wt recipients, but failed to control the GVH reaction
that occurred in B6-MHC II/ recipients. Therefore, while do-
nor CD4CD25 T cells required co-transplantation with synge-
neic MHC II to support donor hematopoietic progenitors, alloge-
neic recipient MHC II was required for suppression of GVHD. In
conclusion, donor CD4CD25 T cells capable of promoting
long-term engraftment and tolerance may have distinct antigenic
requirements from those responsible for GVHD suppression, and
clinical protocols for allogeneic transplantation involving
CD4CD25 T cells should account for their distinct antigenic
requirements.
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ROLE OF IL-2, IL-7, AND IL-15 IN ALLOGENEIC GRAFT-VS-LEUKEMIA
AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA IN A NOD/scid CHIMERIC
MURINE MODEL
Cipkala, D.A., Hendey, L., Boyer, M.W. Columbus Childrens Research
Institute, Columbus, OH.
We studied the GVL effects of human alloreactive CTL against
ALL in a chimeric NOD/scid mouse model. CTL were generated
from random blood donor PBMCs stimulated with the 697 human
ALL cell line and supplemented with IL-2, 7, or 15. CD8
positive T cells comprised the majority of the cultures in each
group: 46% for IL-2, 52% for IL-7, and 45% for IL-15 cultured
CTL (n  13). CTL grown in each cytokine resulted in similar in
vitro cytotoxicity: IL-2 41.3%, IL-7 37.7%, IL-15 45.3%, n 
12-15, and had statistically similar intracellular perforin and gran-
zyme-B expression. IL-7 and IL-15 CTL had statistically higher
bcl-2 levels than IL-2 CTL suggesting better anti-apoptosis and
survival potential. NOD/scid mice were injected with 697 ALL
cells followed by 5  106 CTL. Mice were sacriﬁced seven days
following CTL injection and residual leukemia was measured in
the bone marrow and spleen via ﬂow cytometry. There were two
groups of experiments with different degrees of leukemia engraft-
ment seen at day 21. In one group (low engraftment) mice not
receiving CTL had a baseline leukemia burden of 2.01% and
0.15% in the bone marrow and spleen, respectively (n  15). Mice
treated with IL-15 cultured CTL had a reduction in tumor burden
to 0.2% (n  13, P  .01) and 0.05% (n  13, P  .01) in bone
marrow and spleen, respectively. Those treated with IL-2 or IL-7
cultured CTL showed no signiﬁcant difference in leukemia burden
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